Total amount: € 0,00
Rossi S., Rinaldi M., Romano M., Rinaldi B., D'Amico M., Di Filippo C.
The newly discovered cannabinoids and their endogenous ligand arachidonylethanolamide opened the way to the use of the cannabinoids in medicine, particularly in the glaucoma therapy. Actually, the focus is posed on drugs predominately acting on specific CB1 receptors. These drugs seem to be able to reduce the 1st symp-tom of glaucoma, the ocular hypertension. New technologies such as microemulsion and cyclodextrins based pharmaceutical preparations enable these drugs to topical ophthalmic administration. This would minimize drug concentration in the systemic circulation and possible consequent adverse-side effects (hypotension, tachycardia and psychic disorders).